APW
VKTX icon

Atlantic Private Wealth’s Viking Therapeutics VKTX Stock Holding History

Atlantic Private Wealth’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.3K Hold
500
– – 0.01% 183
2025
Q4 		$17.6K Hold
500
– – 0.01% 176
2025
Q3 		$13.1K Hold
500
– – 0.01% 173
2025
Q2 		$13.3K Hold
500
– – 0.01% 172
2025
Q1 		$12.1K Buy
500
+50
+11% +$1.58K 0.01% 172
2024
Q4 		$18.1K Buy
+450
New +$25.7K 0.01% 147

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Atlantic Private Wealth's VKTX Position: Q1 2026 in Review

Atlantic Private Wealth held its Viking Therapeutics (VKTX) position steady in Q1 2026 at 500 shares worth $16.3K. The position accounts for 0.01% of the portfolio, ranked #183.

Atlantic Private Wealth first reported a position in VKTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $18.1K in Q4 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Atlantic Private Wealth held 500 shares of Viking Therapeutics worth $16.3K as of Q1 2026.
  • Atlantic Private Wealth left its Viking Therapeutics share count unchanged in Q1 2026.
  • Viking Therapeutics made up 0.01% of Atlantic Private Wealth's portfolio in Q1 2026, its #183 holding.
  • Atlantic Private Wealth first reported a position in Viking Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Atlantic Private Wealth's Viking Therapeutics position peaked at $18.1K in Q4 2024.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Atlantic Private Wealth's 13F filing for Q1 2026, filed 8 May 2026.